| answer text |
<p>We are aware of a shortage of triamcinolone hexacetonide 20 milligram/1 millilitre
suspension for injection ampoules, which has been caused by the supplier experiencing
manufacturing issues. We are liaising with the supplier of this product to ensure
that action is taken to resolve this issue, as quickly as possible.</p><p>We have
issued communications to healthcare professionals, providing guidance and advice on
how to manage patients during the shortage. We have also been liaising with the British
Society of Rheumatology, to keep them updated on the supply position. We have well-established
procedures and tools for managing medicine supply issues, whatever the cause, and
we work closely with the Medicines and Healthcare products Regulatory Agency, the
pharmaceutical industry, the National Health Service and others operating in the supply
chain to help prevent shortages and to ensure that the risks to patients are minimised
when shortages do arise.</p>
|
 |
